Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David J. Mazzo
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Beta
- 0.80
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -0.75
Financials
Revenue
$0.00-100.0%Net Income
$-6.79MEBITDA
$-10.03MFree Cash Flow
$-12.68MEPS (diluted)
$-0.73Shares Outstanding (diluted)
9.30M+2031.5%Operating Expenses
$10.03MCash & Debt
$282.72MReturn of Capital
$0.00Revenue by Segment (annual)
$170.0KDividend per Share
$0.31Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $170.0K | $-16.59M | $-1.91 |
| 2024 | $1.00M | $-19.98M | $-2.40 |
| 2023 | $0.00 | $-20.84M | $-2.58 |
| 2022 | $0.00 | $-54.23M | $-10.47 |
| 2021 | $0.00 | $-27.47M | $-7.45 |
| 2020 | $0.00 | $-8.15M | $-7.91 |
| 2019 | $0.00 | $-20.10M | $-29.20 |
| 2018 | $0.00 | $-16.17M | $-25.03 |
| 2017 | $0.00 | $22.98M | $38.43 |
| 2016 | $35.28M | $-32.66M | $-74.81 |
| 2015 | $22.49M | $-80.89M | $-250.12 |
| 2014 | $17.94M | $-54.87M | $-251.28 |
| 2013 | $14.67M | $-38.98M | $-285.29 |
| 2012 | $14.33M | $-54.78M | $-600.00 |
Valuation
LSTAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-62.96%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·3d ago·Neutral
…erapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026 LIBERTY CORNER, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ: LSTA) (“Lisata” or the “Company”) today announced a one-for-fifteen reverse stock split of its common stock. The Company's common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market at the market open on November 23, 2026 under the existing trading symbol “LSTA”. The new CUSIP number for the Company's com…
View source ↗ - Newsproactiveinvestors.com·45d ago·Negative
Lisata Therapeutics wins new US patent for pancreatic cancer drug Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has been granted a new US patent covering its experimental drug certepetide for the treatment of pancreatic cancer and other solid tumors, the company said. The US Patent and Trademark Office issued the Method of Use patent titled "Methods for Treating Pancreatic Cancer and Other Solid Tumors.
View source ↗ - Newsproactiveinvestors.com·59d ago·Neutral
Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions Marea Therapeutics, a subsidiary of Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), said data from the Phase 2b TYDAL study of its lead candidate MAR001 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions 2026 in Chicago. MAR001 is an experimental antibody that blocks a protein called ANGPTL4, which helps fat tissue work properly, with the goal of loweri…
View source ↗ - Newsbenzinga.com·66d ago·Neutral
Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy Lisata Therapeutics, Inc. (NASDAQ:LSTA) on Thursday announced it has acquired clinical-stage biotechnology company Marea Therapeutics, Inc. alongside an oversubscribed $225 million private placement financing.
View source ↗ - Newsproactiveinvestors.com·66d ago·Negative
Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has acquired Marea Therapeutics, a clinical-stage biotech developing next-generation medicines for cardioendocrine diseases. The companies also entered a private placement financing agreement expected to raise approximately $225 million in gross proceeds.
View source ↗ - Newsglobenewswire.com·66d ago·Negative
… and other institutional investors projected to fund operations into 2028 LIBERTY CORNER, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company, today announced that it has acquired Marea Therapeutics, Inc. (“Marea”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases.
View source ↗
Earnings
Thu, Mar 11(in 4 months)
Consensus estimate $-2.17 per share
Typical surprise +9.3% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 13$-0.73 vs $-1.13beat
- Thu, Mar 12$-0.74 vs $-0.51miss
- Thu, Nov 6$-0.49 vs $-0.54beat
- Thu, Aug 7$-0.54 vs $-0.65beat
- Thu, May 8$-0.55 vs $-0.53miss
Estimates and results for LSTA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LSTA officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LSTA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
